All the news Showing 10 of 24 articles from: AASLD 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Therapies Sofosbuvir plus ribavirin shows suboptimal efficacy for acute hepatitis C Liz Highleyman / 25 February 2016 A combination of sofosbuvir (Sovaldi) and ribavirin cured more than 90% of hepatitis C in people living with HIV and acute hepatitis C virus (HCV) infection in a small study, but a similar ... MiR-122 inhibitor RG-101 suppresses hepatitis C virus with a single dose Liz Highleyman / 15 February 2016 A single injection of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log10 in people with HCV genotypes 1, ... Interferon-free regimens Three-drug regimens taken for 8 weeks demonstrate high hepatitis C cure rate Liz Highleyman / 13 January 2016 An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of hepatitis C ... Finance, funding & health economics United States faces biggest burden of hepatitis C treatment costs before 2020 Keith Alcorn / 11 December 2015 The cost of treating hepatitis C (HCV) is likely to decline dramatically over the next decade in the United States, not because of cuts in drug prices but because the population in ... Resistance High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy Liz Highleyman / 09 December 2015 People with hepatitis C who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir ... Fibrosis Coffee consumption linked to reduced liver fibrosis in people with HBV, HCV and NAFLD Liz Highleyman / 08 December 2015 Drinking coffee was associated with lower liver stiffness – a non-invasive measure used to estimate liver fibrosis – in people with hepatitis B, hepatitis C and non-alcoholic fatty liver disease (NAFLD), researchers reported ... Treatment outcomes Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction Keith Alcorn / 04 December 2015 The number of hepatitis C virus (HCV)-related referrals for liver transplant has declined significantly since the introduction of HCV direct-acting antivirals (DAAs), according to two US studies presented to the recent 2015 ... Treatment for people who use drugs Study reveals potential challenges for scaling up of HCV therapy in UK Michael Carter / 03 December 2015 A large proportion of patients with chronic hepatitis C virus (HCV) infection in the UK have co-morbidities, hazardous use of drugs and alcohol and are taking medications that can potentially interact with HCV ... Genotype 1b Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks Liz Highleyman / 02 December 2015 Response-guided therapy using an all-oral regimen of three direct-acting antivirals cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from the small SODAPI pilot study, ... Treatment outcomes Liver fibrosis improves after successful treatment for hepatitis C Liz Highleyman / 02 December 2015 A majority of people with chronic hepatitis C and advanced fibrosis or cirrhosis showed improvement in liver health following treatment, according to study findings presented last week at the 2015 AASLD Liver ... ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive